Zobrazeno 1 - 10
of 6 035
pro vyhledávání: '"antiretrovirals"'
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 23, Iss , Pp 2669-2679 (2024)
HIV-1 can rapidly infect the brain upon initial infection, establishing latent reservoirs that induce neuronal damage and/or death, resulting in HIV-Associated Neurocognitive Disorder. Though anti-HIV-1 antiretrovirals (ARVs) suppress viral load, the
Externí odkaz:
https://doaj.org/article/16081dd8318742cfaf5225af558840bb
Autor:
Emma LaNoce, Daniel Y. Zhang, Alan Garcia-Epelboim, Yijing Su, Yusha Sun, Giana Alepa, Angelina R. Angelucci, Cagla Akay-Espinoza, Kelly L. Jordan-Sciutto, Hongjun Song, Guo-li Ming, Kimberly M. Christian
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 17 (2024)
IntroductionFor many therapeutic drugs, including antiretroviral drugs used to treat people living with HIV-1 (PLWH), we have little data on the potential effects on the developing human brain due to limited access to tissue and historical constraint
Externí odkaz:
https://doaj.org/article/474d3437c0cf49128cbae36e4c3182d6
Autor:
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CAR
Externí odkaz:
https://doaj.org/article/cf663c19fbc04c13b44fe74a60666e97
Autor:
Xiaowei Chen, Xiao Wang
Publikováno v:
Retrovirology, Vol 21, Iss 1, Pp 1-7 (2024)
Abstract The p6 domain of the Gag precursors (Gag p6) in human immunodeficiency virus type 1 (HIV-1) plays multifunctional roles in the viral life cycle. It utilizes the endosomal sorting complex required for transport (ESCRT) system to facilitate vi
Externí odkaz:
https://doaj.org/article/cbb1b21c1aba442783fbd6655e962360
Autor:
Jesse Ross, Rubeshan Perumal, Allison Wolf, Mbali Zulu, Kevin Guzman, Boitumelo Seepamore, Karl Reis, Hlengiwe Nyilana, Senzo Hlathi, Radhamoney Narasimmulu, Ying Kuen K. Cheung, K. Rivet Amico, Gerald Friedland, Amrita Daftary, Jennifer R. Zelnick, Kogieleum Naidoo, Max R. O’Donnell
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Highly effective, short-course, bedaquiline-containing treatment regimens for multidrug-resistant tuberculosis (MDR-TB) and integrase strand transfer inhibitor (INSTI)-containing fixed dose combination antiretroviral therapy (ART)
Externí odkaz:
https://doaj.org/article/70a2d6eccade4823b60ce2ce9803d3a8
Autor:
Shreya H. Dhume, Kayode Balogun, Ambalika Sarkar, Sebastian Acosta, Howard T. J. Mount, Lindsay S. Cahill, John G. Sled, Lena Serghides
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 17 (2024)
BackgroundCombination antiretroviral therapy (ART) use in pregnancy has been pivotal in improving maternal health and reducing perinatal HIV transmission. However, children born HIV-exposed uninfected fall behind their unexposed peers in several area
Externí odkaz:
https://doaj.org/article/bce873f96d344bb199afb41b22cba351
Publikováno v:
Southern African Journal of HIV Medicine, Vol 24, Iss 1, Pp e1-e7 (2023)
Background: Protease inhibitors (PIs) have been recommended as World Health Organization second-line antiretroviral therapy (ART) for low- to middle-income countries for two decades. As dolutegravir-based regimens have become widely available, the fu
Externí odkaz:
https://doaj.org/article/ff21e0eb408b4d2da1fc25a794f11fc6
Autor:
Ying Zhang, Mark Bush, Parto Yazdani, Joyce Zhan, Bo Wen, Veronica Bainbridge, Brian R. Wynne, Samit Joshi, Max Lataillade
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 6, Pp n/a-n/a (2023)
Abstract GSK3640254 (GSK'254) is a novel HIV‐1 maturation inhibitor with pharmacokinetics supporting once‐daily (QD) therapy for HIV‐1 treatment. This thorough QT/corrected QT (QTc) study evaluated the effect of GSK'254 on cardiac repolarizatio
Externí odkaz:
https://doaj.org/article/5191d91a05ac43c2a70b1bf6d821069a
Autor:
Lauren Jennings, Rebecca L. West, Nafisa Halim, Jeanette L. Kaiser, Marya Gwadz, William B. MacLeod, Allen L. Gifford, Jessica E. Haberer, Catherine Orrell, Lora L. Sabin
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background South Africa bears a large HIV burden with 7.8 million people with HIV (PWH). However, due to suboptimal antiretroviral therapy (ART) adherence and retention in care, only 66% of PWH in South Africa are virally suppressed. Standar
Externí odkaz:
https://doaj.org/article/41977d481ce743e98efbb46282851c94
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Background Lamivudine (LAM) and tenofovir disoproxil fumarate (TDF) are part of a fixed-dose combination (FDC) therapy recommended by WHO. Both drugs exhibit similar solubility in many solvent systems and tend to have overlapping spectra wit
Externí odkaz:
https://doaj.org/article/09b525c8571348cfbe17a398bce5a5ed